Fig. 3. Forest plots of cardiovascular safety end points (romosozumab vs placebo). (A) Odds ratio for composite cardiovascular diseases, (B) Odds ratio for major adverse cardiovascular events

Korean J Clin Pharm 2023;33:128-34 https://doi.org/10.24304/kjcp.2023.33.2.128

© 2023 Korean J Clin Pharm